Skin Specific Outcomes at Week 52
| Endpoints, data is presented as % response | SEC 300 mg (N = 215) | ADA 40 mg (N = 202) | P-value (unadjusted) |
|---|---|---|---|
| PASI 100 | 46·0 | 29·7 | 0·0007 |
| Absolute PASI score ≤3 | 79·2 | 65·0 | 0·0015 |
P value vs. adalimumab; Unadjusted P values are presented
N, number of patients in psoriasis subset
Multiple imputation was used for handling missing data
ADA, adalimumab; BSA, body surface area; PASI, psoriasis area severity index; SEC, secukinumab